Has Kimberly Hashemi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,257 in general payments to Kimberly Hashemi, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kimberly Hashemi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kimberly Hashemi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kimberly Hashemi, MD

Dermatology · Charleston, SCNPI 1356900807

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in SC, where the typical reported total is $3,326.

$1,257in general payments, 2019–2025

Across 15 payments — averaging $83.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$207
AbbVie$182
Sun Pharmaceutical Industries Inc.$136
Galderma Laboratories, L.p.$124
Sanofi$123
UCB, Inc.$117
plus $368 from 5 others

$117,931in research payments, 2019–2025

Across 7 payments — averaging $16,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Astrazeneca UK Limited$50K
AstraZeneca$36K
AbbVie$30K
Pfizer$2K

What the payments were for

Travel & lodging$786%
Food & beverage$1,17994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	2	$207
AbbVie	2	$182
Sun Pharmaceutical Industries Inc.	2	$136
Galderma Laboratories, L.p.	1	$124
Sanofi	2	$123
UCB, Inc.	1	$117
Axsome Therapeutics, Inc.	1	$115
Incyte Corporation	1	$90
Novartis	1	$80
Johnson & Johnson	1	$64
LEO Pharma Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,257 in reported general payments places this provider in the 30th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$43,052

Medicare patients

172

Services billed

676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	18	$340,602
Taltz AutoinjectorIxekizumab	22	$157,159
SotyktuDeucravacitinib	11	$70,179
Dupixent PenDupilumab	11	$52,476
Mycophenolic AcidMycophenolate Sodium	14	$4,113
Mycophenolate Mofetil	12	$1,822
Tacrolimus	13	$1,590
Clobetasol Propionate	21	$1,335
Triamcinolone Acetonide	28	$523
Ketoconazole	29	$522
MethotrexateMethotrexate Sodium	12	$343
Mupirocin	19	$192

Paid to pharmacies, not to this prescriber.

Other dermatology in Charleston

Todd SchlesingerCharleston$1.9M
Mark SiegelCharleston$120K
Erin WalkerCharleston$20K
Alan SnyderCharleston$13K
David SmithCharleston$12K
Marshall ShulerGreenville$2.6M
Rebecca SmithFort Mill$2.3M
Amylynne FrankelSpartanburg$987K
Marguerite GermainMt Pleasant$200K
George KeoughPawleys Island$150K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →